KARD (46) OPK (40) DMRA (35) NKTR (20) ⌘ Pro Terminal →

LB Pharmaceuticals Inc (LBRX) — RQD Stock Rating Cockpit

$39.70 -1.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $39.54

LB Pharmaceuticals Inc (LBRX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.28B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LBRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, LB Pharmaceuticals Inc (NASDAQ: LBRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $39.70 (-1.12% 1D, market cap $1.28B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LBRX ranks #483 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LBRX compare to KARD and OPK in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LBRX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -8.4%. By comparison, KARD (Kardigan Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.32B) and OPK (OPKO Health Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B). Among the 5-stock peer group, LBRX leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LBRX?

▼

Per LBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001691082), LB Pharmaceuticals Inc generated $0 in revenue, -$25.2M in net income, and -$35.3M in free cash flow against $312.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $39.55 (-0.39%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LBRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY LBRX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$34.79+17.8% Next Q

Q2 (-2Q)

Grade E$41.00-3.3% Next Q

Q3 (-1Q)

Grade E$39.64+0.2% Next Q

Current

Grade D-$39.70-7.6% Hist 90D α

Trajectory: E (31) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LBRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LBRX currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($41.06) and Max Pain ($41.69) forces dealer call-delta covering toward $52.67.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LBRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LBRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

52.630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE71% OF RANGE

L: $14$39.70H: $50

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LBRX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-8.4% ROIC with 42.0% gross margin and -2.72% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (40)

14/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like LBRX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LBRX)

✓Walkthrough of LBRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LBRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.73%⚡ TESTING RESISTANCE

2026-11-03O $40.15H $40.15L $39.70C $39.70VOL 429.5K

RES: $40.44SUP: $34.50SMA50: $41.06SMA200: $32.77

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LBRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LBRX Butterfly Map → + Track LBRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LBRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LBRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LBRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LBRX)

Health Care Rank #483 of 1016 ⚔️ KARD vs LBRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LBRX vs. KARD, OPK, DMRA, NKTR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LB Pharmaceuticals Inc (LBRX) ranks #483 by composite RQD confidence (39/100, grade D-) and #326 by equity capitalization ($1.28B). Within this direct 5-issuer industry benchmark cohort, LBRX leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with LBRX at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LBRX ACTIVE LB Pharmaceuticals Inc	D-	39/100	—	—	-8.4%	-1.12%	$1.28B	Benchmark Subject
KARD Kardigan Inc.	D	46/100	—	—	—	-1.26%	$1.32B	/kard-vs-lbrx →
OPK OPKO Health Inc.	D-	40/100	—	33.9%	-10.2%	0.00%	$1.24B	/opk-vs-lbrx →
DMRA Damora Therapeutics Inc.	D-	35/100	—	—	-35.0%	-2.36%	$1.33B	/dmra-vs-lbrx →
NKTR Nektar Therapeutics	E	20/100	—	96.0%	-35.0%	-0.79%	$1.33B	/nktr-vs-lbrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001691082

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LB Pharmaceuticals Inc (LBRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$25.2M, operating cash flow of -$35.2M, and free cash flow of -$35.3M (+34.5% YoY). On the balance sheet, LBRX closed FY2025 with $312.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$25.2M	-$35.2M	-$35.3M	$312.9M	—
FY2024 (FY)	2024-12-31	$0	-$63.1M	-$53.1M	-$53.8M	$33.5M	—

3. LBRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LBRX compare to KARD and OPK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LBRX?

Where is LBRX trading relative to its 50-day, 200-day, and 52-week technical levels?

LBRX last traded at $39.70 (-1.12% on volume of 429,484 shares), positioning the stock -3.31% below its 50-day simple moving average ($41.06) and +21.15% above its 200-day simple moving average ($32.77). Across its 52-week range of $14.32 to $50.16, LBRX sits at the 70.8% percentile with a 14-day RSI of 52.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($34.74 to $44.66).

LBRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LBRX stock right now?

LB Pharmaceuticals Inc (LBRX) currently earns a Roarable Rating of D- (Sell — SELL) with 39/100 RQD Confidence. Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.

What is LBRX's 12-month price target and RQD AI Jury consensus?

LBRX's 12-month base price target is $36.31 (range $28.32 to $52.67), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LBRX RQD Cockpit LBRX 12M Forecast LBRX Earnings & Move LBRX Dividends & DRIP LBRX Insiders & 13F LBRX Whale Options LBRX Profit Sankey LBRX News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LBRX — LB Pharmaceuticals Inc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:29:47Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LBRX carries a score of 41 out of 100 and a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 5 of 20, reflecting an ROIC of -8.4% and an FCF yield of -2.72%, which signals that the business is not currently generating returns on capital or positive free cash flow. The whale/13F flow pillar scores 13 of 20 for institutional accumulation and options positioning, the strongest pillar, suggesting some institutional interest that partially offsets weak fundamentals. Insider conviction scores 3 of 20 based on SEC Form 4 and Congressional PTR cluster flow, indicating little insider signal of confidence. The macro regime fit pillar scores 10 of 20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 10 of 20, citing an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. For a prospective investor, the implication is that upside drivers are not evident in the reported cash-generation data, valuation cannot be anchored to earnings because the company reports net losses, and the balance sheet provides some cushion but weak forensic signals warrant caution.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the items are:

Guggenheim reiterates LB Pharmaceuticals stock rating on study data (Investing.com; YELLOW, MARKET WIRE). Indicates an analyst reiteration tied to study data; the rating itself is not specified in source data.
LB Pharmaceuticals Stock Forecast & Analyst Predictions (Simply Wall St; YELLOW, MARKET WIRE). A forecast-oriented report; no specific figures provided.
Stock Price Down 5.4% Following Analyst Downgrade (MarketBeat; RED, RISK WATCH). The sole RISK WATCH item, citing a downgrade and a 5.4% price decline.
Analysts Offer Insights on NA Companies (The Globe and Mail; YELLOW, MARKET WIRE). Multi-company analyst commentary including LBRX.
200,000-share option award for the CFO carries a $37.22 exercise price (Stock Titan; YELLOW, MARKET WIRE). A compensation-related item.
Stock Price Down 7% - Here's What Happened (MarketBeat; YELLOW, MARKET WIRE). A reported 7% decline without stated cause in the summary.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What are LBRX's products, clinical programs, and revenue model, given that reported revenue is $0.0M in both periods?
What drove the $250.2M cash balance in FY 2025 versus $23.0M in FY 2024, and is it from financing or other sources?
What is the total debt figure, since the debt field is N/A despite a Debt/Equity ratio of 0.5?
What were the specifics of the analyst downgrade and the Guggenheim study-data reiteration?
What are the current consensus rating and price targets, given the analyst data section is empty?

LBRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LB Pharmaceuticals Inc (LBRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LBRX Debate Forum (3) ↓

🟡 MARKET WIRE Investing.com • 18h ago

Guggenheim reiterates LB Pharmaceuticals stock rating on study data

Investing.com report covering LB Pharmaceuticals Inc (LBRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 21h ago

LB Pharmaceuticals (NasdaqGM:LBRX) Stock Forecast & Analyst Predictions

Simply Wall St report covering LB Pharmaceuticals Inc (LBRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 1d ago

LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 5.4% Following Analyst Downgrade

MarketBeat report covering LB Pharmaceuticals Inc (LBRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Analysts Offer Insights on NA Companies: SpaceX (SPCX), Six Flags Entertainment Corporation (FUN) and LB Pharmaceuticals, Inc. (LBRX)

The Globe and Mail report covering LB Pharmaceuticals Inc (LBRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A 200,000-share option award for LB Pharmaceuticals (LBRX) CFO carries a $37.22 exercise price.

Stock Titan report covering LB Pharmaceuticals Inc (LBRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 7% - Here's What Happened

MarketBeat report covering LB Pharmaceuticals Inc (LBRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

LB Pharmaceuticals (LBRX) Slips to $34.37 but Holds Above Key $32.65 Support - High Beta Stocks

https://www.siam.in/ report covering LB Pharmaceuticals Inc (LBRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $57.40 According to Analysts

MarketBeat report covering LB Pharmaceuticals Inc (LBRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LBRX Bull vs. Bear Conversation Board — What's Your Call at $39.70?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LBRX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $35.33 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LBRX (D- • RQD 41/100) a Buy at $40.15?

Welcome to the LBRX (LB Pharmaceuticals Inc) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $32.92 (-18.0%)

Spot @ $40.15

Pump the brakes on LBRX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LBRX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless LB Pharmaceuticals Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $46.57 (+16.0%)

Spot @ $40.15

LBRX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LBRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $40.15 (52-wk range $14.32 - $50.16), any beat on forward guidance forces shorts and underweight funds to chase.